638 results on '"Newell-Price, John"'
Search Results
2. COVID-19 pandemic and adrenals: deep insights and implications in patients with glucocorticoid disorders
3. Quality of Life in Post-Surgical Hypoparathyroidism (PoSH) in Thyroid and Parathyroid Surgery
4. Changing the name of diabetes insipidus
5. Central diabetes insipidus from a patient's perspective: management, psychological co-morbidities, and renaming of the condition: results from an international web-based survey
6. Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study
7. Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol.
8. A Retrospective Study on Weaning Glucocorticoids and Recovery of the Hypothalamic–Pituitary–Adrenal Axis.
9. Maximising the sensitivity of bilateral inferior petrosal sinus sampling
10. Biochemical control with dose reduction in chronic glucocorticoid therapy over 4 years: A phase III extension study of Chronocort (Efmody) in the treatment of Congenital Adrenal Hyperplasia (CAH)
11. Improvements in diabetes and hypertension were sustained over long-term osilodrostat treatment in patients with Cushing's disease: A pooled analysis of LINC 3 and LINC 4
12. CHAMPAIN study: Initial results from a phase II study of efficacy, safety and tolerability of modified-release hydrocortisones: Chronocort® (Efmody®) versus Plenadren®, in primary adrenal insufficiency
13. Morning cortisol levels in patients with established primary adrenal insufficiency
14. Consensus on diagnosis and management of Cushing's disease: a guideline update
15. Cushing's syndrome
16. Approach to the Patient With Suspected Hypotonic Polyuria.
17. Long-term safety of gamma knife radiosurgery (SRS) for acromegaly
18. Participants aux Davidson's Principles and Practice of Medicine, 23eédition
19. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase
20. Changing the name of diabetes insipidus: a position statement of the working group to consider renaming diabetes insipidus.
21. Cushing's Syndrome
22. Cushing's disease—from Minnie G to key issues in the early 21st century
23. Therapy of mild cortisol excess
24. Advances in the medical treatment of Cushing's syndrome
25. Medical management of Cushing's disease
26. Contributors
27. Testing for Arginine Vasopressin Deficiency
28. New Molecular Targets for Treatment of Cushing’s Disease
29. Efficacy and safety of once-monthly pasireotide in Cushing's disease: a 12 month clinical trial
30. Multivariable Model to Predict an ACTH Stimulation Test to Diagnose Adrenal Insufficiency Using Previous Test Results
31. OR30-01 Waking Salivary 11-hydroxyandrostenedione And Cortisone As A Novel Non-invasive Test For Adrenal Insufficiency
32. THU038 Osilodrostat Dosing In Cushing’s Disease: A Pooled Analysis Of The LINC Program
33. SAT304 Improved Biochemical Control With Dose Reduction In Chronic Glucocorticoid Therapy: A Phase III Extension Study Of Chronocort (Efmody) In The Treatment Of Congenital Adrenal Hyperplasia (CAH)
34. Comorbidities in mild autonomous cortisol secretion and the effect of treatment: systematic review and meta-analysis
35. Endocrine problems in the critically ill 2: endocrine emergencies
36. Cushing's syndrome
37. Adrenocortical incidentalomas and bone: from molecular insights to clinical perspectives
38. A prospective longitudinal study of Pasireotide in Nelson’s syndrome
39. Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium
40. European Society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal Tumors
41. Retrospective study of steroid weaning in tertiary adrenal insufficiency comparing prednisolone and hydrocortisone
42. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
43. Pro: Should diabetes insipidus be re-named?
44. Pooled analysis from two osilodrostat Phase III studies in Cushing's disease (LINC 3 and LINC 4): Clinical improvements according to urinary and late-night salivary cortisol levels
45. Pooled analysis of osilodrostat dosing across LINC 2, LINC 3 and LINC 4 in Cushing's disease
46. Complications of Cushing's syndrome: state of the art
47. Natural history of non-functioning pituitary microadenomas - results from the UK NFPA consortium
48. Switching patients with Congenital Adrenal Hyperplasia to Modified release hydrocortisone capsules: relative bioavailability and disease control
49. Thyroid disease
50. Infertility
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.